A plain-English look at Thermo Fisher Scientific's business lines, revenue, profit, and market value based on public filings and market data.
A Company Behind the Lab Bench
Walk into almost any hospital lab, university research center, or pharmaceutical plant in the country, and there's a good chance some piece of equipment or reagent came from Thermo Fisher Scientific. The Waltham, Massachusetts-based company doesn't make headlines the way consumer brands do, but it quietly supplies the tools that scientists use to run experiments, diagnose disease, and manufacture medicines.
Four Lines of Business
Thermo Fisher's revenue comes from four segments. Life science solutions is the largest single piece at 23% of sales, followed by analytical technologies at 17% and specialty diagnostic products at 11%. The remainder, which includes contract research organization (CRO) services, falls under lab products and services. Together these businesses cover everything from scientific instruments and diagnostics consumables to laboratory reagents.
What the Revenue Numbers Show
In its FY2025 fiscal year, Thermo Fisher reported $44.6 billion in revenue. That figure has grown 14% since FY2021, a pace that reflects steady expansion rather than a sudden spike. For a company operating across so many scientific fields — from instrument makers to diagnostic suppliers — that kind of multi-year growth suggests demand for its products has broadened over time rather than depending on any single business line.
Profitability in Plain Terms
The company turned that revenue into $6.7 billion in net income for FY2025. In simple terms, for every dollar of sales, Thermo Fisher kept roughly 15 cents as profit after all expenses. That's a healthy margin for a company of this size and signals the business is solidly profitable, not just growing on paper.
Size on the Balance Sheet
Thermo Fisher's total assets stand at $110.3 billion — more than double its annual revenue. That scale reflects a company built through decades of investment in manufacturing facilities, laboratory infrastructure, and acquisitions across the life sciences industry.
How the Market Values It
Investors currently value Thermo Fisher at a market capitalization of $175.7 billion, with shares recently trading around $517.60. That valuation works out to a price-to-earnings ratio of 29.2, meaning the stock trades at about 29 times the company's annual earnings — a way of expressing how much the market is willing to pay today for each dollar of current profit. Shares are currently trading 19% below their 52-week high.
Dividend and Ownership
Thermo Fisher pays a dividend yielding about 0.36% annually, a modest payout relative to its share price. The company has traded publicly on the New York Stock Exchange under the ticker TMO since its original IPO in June 1972, though the company in its current form dates to 2006. It employs approximately 125,000 people worldwide.
Where the Company Stands Today
Operating in the medical devices industry broadly, Thermo Fisher occupies a position few companies can claim: it sells to nearly every corner of the scientific world, from academic labs to pharmaceutical manufacturers to diagnostic clinics. Its financial profile — steady revenue growth, solid profitability, and a large asset base — reflects a mature company built around the everyday tools of scientific and medical work.
A Note on This Report
This article is factual reporting drawn from public filings and market data, not investment advice.
